主要文件

查看所有文档

Y0001252

美罗培南三水合物

Name: 美罗培南三水合物
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

(1R,5S,6S)-2-[(3S,5S)-5-（二甲氨基羰基）吡咯烷-3-基硫]-6-\ [( R )-1-羟乙基]-1-甲基碳青霉烯-2-烯-3-羧酸三水合物

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₇H₂₅N₃O₅S · 3H₂O

化学文摘社编号:

119478-56-7

分子量:

437.51

NACRES:

NA.24

PubChem Substance ID:

329831324

UNSPSC Code:

41116107

MDL number:

MFCD08600005

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

meropenem

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O.O.O.C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O

InChI

1S/C17H25N3O5S.3H2O/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4;;;/h7-12,18,21H,5-6H2,1-4H3,(H,24,25);3*1H2/t7-,8-,9+,10+,11-,12-;;;/m1.../s1

InChI key

CTUAQTBUVLKNDJ-OBZXMJSBSA-N

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Meropenem trihydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

美罗培南三水合物是一种对革兰阳性菌和革兰阴性菌均有活性的超广谱 β-内酰胺类抗生素。

美罗培南三水合物是一种超广谱 β-内酰胺类抗生素。

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under 美罗培南三水合物

pictograms

GHS08

signalword

Danger

hcodes

H317,H334

pcodes

P261 - P272 - P280 - P284 - P302 + P352 - P333 + P313

Hazard Classifications

Resp. Sens. 1 - Skin Sens. 1

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

涉药品监管产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.

Laurens Manning et al.

PloS one, 9(7), e102023-e102023 (2014-07-16)

Concerns regarding the clinical impact of meropenem instability in continuous infusion (CI) devices may contribute to inconsistent uptake of this method of administration across outpatient parenteral antimicrobial therapy (OPAT) services. We retrospectively reviewed the clinical efficacy and safety of CIs

Light-Activated Rhenium Complexes with Dual Mode of Action against Bacteria.

Angelo Frei et al.

Chemistry (Weinheim an der Bergstrasse, Germany), 26(13), 2852-2858 (2019-12-04)

New antibiotics and innovative approaches to kill drug-resistant bacteria are urgently needed. Metal complexes offer access to alternative modes of action but have only sparingly been investigated in antibacterial drug discovery. We have developed a light-activated rhenium complex with activity

Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation.

Johannes Zander et al.

Clinical chemistry and laboratory medicine, 53(5), 781-791 (2014-10-11)

Recent studies have demonstrated highly variable blood concentrations of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in critically ill patients with a high incidence of sub-therapeutic levels. Consequently, therapeutic drug monitoring (TDM) of these antibiotics has to be considered, requiring

全球贸易项目编号

货号	GTIN
Y0001252	04061837584145